Oncotarget · 2017 · 12 citations · 28 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyTumor ProgressionCancer BiomarkersCancer Molecular PathologyCancer ProteomicsCancer Survival AnalysisMalignant NeoplasmsMolecular Tumor ProfilingClinical Outcome MeasurementMeta-analytic Subgroup AnalysisPooled Hazard RatiosPooled Odds RatiosPrognostic Expression SignaturesPrognostic Factors AnalysisPrognostic Marker EvaluationSubgroup Meta-regression
// Yang-xi Ou 1, * , Fang-teng Liu 1, 2, * , Fang-ying Chen 3 and Zheng-ming Zhu 1 1 Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi Province, P. R. China 2 Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, P. R. China 3 The Health Centers of Fengzhou Town, Quanzhou 36200, Fujian Province, P. R. China * These authors have contributed equally to this work Correspondence to: Zhengming Zhu, email: zzm8654@163.com Keywords: Flotillin-1, carcinoma, prognosis, meta-analysis Received: December 21, 2016 Accepted: March 16, 2017 Published: April 13, 2017 ABSTRACT Background: In numerous studies, Flotillin-1 was reported to be involved in tumor progression, indicating prognosis in various types of cancer. However, the results were inconsistent. Results: A total of 2473 patients from 13 articles were included. The results indicated that: (1) Patients detected with high expression level of Flotillin-1 protein had a significantly shorter OS (HR =1.64; 95%CI: 1.39-1.88), statistical significance was also observed in subgroup meta-analyses stratified by the cancer type, nationality, detecting method, cutoff value, analysis type, sample size and publication date. (2) Patients with high Flotillin-1 protein expression level had a poorer DFS (HR = 2.49; 95%CI: 1.64-3.35), a worse RFS(HR = 3.26; 95%CI: 1.10-5.43) and a potential shorter PFS(HR = 1.84; 95%CI: 0.81-2.87). (3) The pooled odds ratios (ORs) showed that increased Flotillin-1 level was also related to lymph node metastasis (OR =6.30; 95% CI: 3.15-12.59), distant metastasis (OR =6.02; 95% CI: 1.50-24.06) and more advanced TNM stage (OR =4.69; 95% CI: 2.74-8.03). Materials and methods: A comprehensive retrieval was performed in multiple databases, including PubMed, Embase, Web of Science and CNKI. The relevant articles were screened for investigating the association between increased Flotillin-1 expression level and prognosis. Additionally, clinicopathological features data was also extracted from these studies. Conclusions: High expression level of Flotillin-1 protein was correlated with poorer clinical outcome. It might serve as a prognostic biomarker and a potential predictive factor of clinicopathology in various tumors. Further well-designed clinical studies should be performed to verify the clinical utility of Flotillin-1 in human solid tumors.
28
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Lawrence Rajendran, Madhan Masilamani, Samuel G. Solomon et al. · Proceedings of the National Academy of Sciences · 2003 · 134 citations · Full text
Monia Amaddii, Melanie Meister, Antje Banning et al. · Journal of Biological Chemistry · 2012 · 129 citations · Full text
Lipid raft-targeted therapy in multiple myeloma
Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate et al. · Oncogene · 2010 · 123 citations
Medicine, Cancer Biology, Oncology +14